Will immunotherapy add value to chemotherapy for HER-2 positive gastric cancer?

[News]

The prognosis for patients with gastric cancer is poor. In western countries even patients with localized gastric or gastro-esophageal junction adenocarcinoma are faced with 5-year survival rates of...

More... (http://www.medicalnewstoday.com/releases/302646.php)